FDA guides on abuse-deterrent opioids; generics direction pending

The FDA on 1 April unveiled its final guidance advising makers of brand-name opioids about what they need to do to obtain abuse-deterrent language in the labeling of their products.

The FDA on 1 April unveiled its final guidance advising makers of brand-name opioids about what they need to do to obtain abuse-deterrent language in the labeling of their products.

The document, Guidance for Industry: Abuse-Deterrent Opioids – Evaluation and Labeling, describes the FDA's expectations about what types of studies...

More from Neurological

More from Therapy Areas

Supernus Secures Sage With CVR-Supported Deal

 

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By 

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.